Pfizer Will Ask FDA to Approve Its COVID-19 Vaccine for Children Under 5 Years
TUESDAY, Feb. 1, 2022 (HealthDay News) — Pfizer Inc. plans to ask the U.S. Food and Drug Administration as soon as Tuesday to authorize its COVID-19 vaccine for emergency use in children aged 6 months to 4 years old.If approved, the two-shot regimen …
Learn MoreWeight Loss in Adulthood Tied to Reduced Risk of Colorectal Adenoma
TUESDAY, Feb. 1, 2022 (HealthDay News) — Weight loss in adulthood is associated with reduced risk of incident distal colorectal adenoma, according to a study published online Feb. 1 in JNCI Cancer Spectrum.Shishi He, from the University of Maryland S…
Learn MorePrevalence of Melatonin Supplement Use Increased Over Time
TUESDAY, Feb. 1, 2022 (HealthDay News) — The reported prevalence of melatonin supplement consumption increased significantly from 1999-2000 to 2017-2018, with prevalence of use of more than 5 mg/day also increasing, starting in 2005 to 2006, accordin…
Learn MoreEUS-Guided Drainage Studied in Noncholecystitis Gallbladder Disease
TUESDAY, Feb. 1, 2022 (HealthDay News) — For patients with noncholecystitis (NC) gallbladder disease who are poor surgical candidates, endoscopic ultrasound‑guided transluminal gallbladder drainage (EUS-GBD) appears to be safe and effective for manag…
Learn MoreExcess Body Fat Tied to Lower Cognitive Scores in Adults
TUESDAY, Feb. 1, 2022 (HealthDay News) — Both generalized and visceral adiposity are associated with lower cognitive scores throughout midlife, according to a study published online Feb. 1 in JAMA Network Open.Sonia S. Anand, M.D., Ph.D., from McMast…
Learn MoreRacial Disparity Seen in Initiation of Newer Diabetes Meds
TUESDAY, Feb. 1, 2022 (HealthDay News) — Black and American Indian or Alaskan Native individuals have significantly lower rates of initiation of newer diabetes medication, according to a study published in the February issue of The Lancet Regional He…
Learn MoreAdding ADT to Radiotherapy Ups Mets-Free Survival in Prostate Cancer
TUESDAY, Feb. 1, 2022 (HealthDay News) — The addition of androgen-deprivation therapy (ADT) to radiotherapy and adjuvant ADT prolongation improve metastasis-free survival in men with localized prostate cancer, according to a meta-analysis published online Jan. 17 in The Lancet Oncology.
Amar U. Kishan, M.D., from the University of California Los Angeles, and colleagues conducted a meta-analysis to quantify the benefit of various ADT intensification strategies in men receiving radiotherapy for treatment of prostate cancer in aggregate and clinically relevant subgroups. Data were included from 12 eligible trials, which provided individual patient data for 10,853 patients, with a median follow-up of 11.4 years.
The researchers observed a significant improvement in metastasis-free survival with the addition of ADT to radiotherapy (hazard ratio, 0.83; 95 percent confidence interval, 0.77 to 0.89; P
“We provide the strongest level of evidence for the routine recommendation for the addition of ADT to radiotherapy in men with intermediate-risk disease, and the use and prolonged adjuvant ADT for men with high-risk disease, irrespective of radiotherapy dose,” the authors write. “However, the strategy of prolongation of neoadjuvant ADT should not be routinely recommended.”
Several authors disclosed financial ties to the biopharmaceutical and medical device industries.
Abstract/Full Text (subscription or payment may be required)
Learn MoreRemdesivir Offers Some Benefit for Hospitalized COVID-19 Patients
TUESDAY, Feb. 1, 2022 (HealthDay News) — Among hospitalized COVID-19 patients, remdesivir added to standard care does not reduce in-hospital mortality, but it does reduce the need for mechanical ventilation, according to a study published online Jan….
Learn MoreSARS-CoV-2 Antibody Tests Should Not Be Used for Diagnosis
TUESDAY, Feb. 1, 2022 (HealthDay News) — Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests should not be used for diagnosis of infection nor to predict natural immunity against reinfection, and, prior to emergence of the del…
Learn MorePolygenic Score Helps Guide Choice of Chemo for Pediatric AML
TUESDAY, Feb. 1, 2022 (HealthDay News) — A polygenic score derived from pharmacogenomic evaluation of cytarabine (ara-C) pathway can help personalize treatment for pediatric patients with acute myeloid leukemia (AML), according to a study published o…
Learn More